CF PharmTech, Inc. (HKEX: 02652) has filed a Next Day Disclosure Return detailing the on-market repurchase of 64,500 H shares on 28 May 2026. Key points are as follows:

• Transaction details: Shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 19.40 to HKD 20.36, with a volume-weighted average cost of HKD 20.04 per share. Aggregate consideration totalled HKD 1.29 million.

• Impact on share capital: – Issued shares (excluding treasury shares) declined from 301.12 million to 301.05 million. – Treasury shares increased from 1.11 million to 1.17 million. – Total issued share count remained unchanged at 302.22 million. – The latest buyback represents 0.0214% of the company’s issued shares (excluding treasury shares).

• Repurchase mandate utilisation: Under the mandate approved on 16 December 2025, CF PharmTech is authorised to repurchase up to 30.22 million shares. Cumulative repurchases now stand at 1.17 million shares, representing 0.39% of the issued share base at the time the mandate was granted, leaving roughly 29.05 million shares available for future buybacks.

• Moratorium: Following the 28 May repurchase, the company is restricted from issuing new shares or selling treasury shares on the market until 27 June 2026, unless prior approval is obtained from the Hong Kong Stock Exchange.

• Compliance confirmation: The board affirmed that the transaction was executed under the existing repurchase mandate and in full compliance with Hong Kong Listing Rules and all relevant regulatory requirements.